Cancer Research

Bristol-Myers Squibb Welcomes NICE Guidance Recommending Baraclude(R) (entecavir) As A Treatment Option For Chronic Hepatitis B

UXBRIDGE, England, August 29 /PRNewswire/-- NICE (National Institute for Health and Clinical Excellence) has published guidance that recommends Baraclude(R) (entecavir) as an option for treatment of eligible patients with chronic hepatitis B (CHB). Enteca ...

Article - Anna Ohlden - Aug 29 2008 - 5:30am

Discovery- 'Mother' Of All Blood Stem Cells

Johns Hopkins researchers say they have discovered the earliest form of human blood stem cells and deciphered the mechanism by which these embryonic stem cells replicate and grow. They also found a surprising biological marker that pinpoints these stem cel ...

Article - News Staff - Aug 29 2008 - 4:53pm

Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events In Diabetes Patients By 30 Percent Compared With Clopidogrel

MUNICH, Germany, August 31 /PRNewswire/--- Sub-group analysis of landmark trial showed prasugrel substantially reduced risk of heart attack and stent thrombosis compared with clopidogrel among ACS patients with diabetes ...

Article - Anna Ohlden - Aug 31 2008 - 8:33am

British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines

BURGESS HILL, England, September 1 /PRNewswire/-- With some 20,000 UK children with Type 1 diabetes(i) about to start the new school year, new guidance from the National Institute for Health and Clinical Excellence (NICE) looks set to revolutionise the wa ...

Article - Anna Ohlden - Aug 31 2008 - 6:33pm

This Day In Science History: August 31st

Scientific happenings, big and small, on this day in history But first, today’s quiz: The answer may seem obvious, but don’t be fooled – it’s not what you think. On this day in 1886, the first earthquake on record with significant human consequence (over 1 ...

Article - Kimberly Crandell - Sep 1 2008 - 1:24pm

Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial For Non-Small Cell Lung Cancer Patients With K-RAS Or

CALGARY, Canada, September 2 /PRNewswire/-- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial usin ...

Article - Anna Ohlden - Sep 2 2008 - 1:30am

50 Year Cell Division Mystery Solved, Say Researchers

Researchers from Oregon State University say they have resolved a controversy that cellular biologists have been arguing over for nearly 50 years, with findings that may aid research on everything from birth defects and genetic diseases to the most classic ...

Article - News Staff - Sep 2 2008 - 10:47pm

Male Height Linked To Prostate Cancer Risk (Sort Of)

A man's height is a marker for risk of prostate cancer development but is more strongly linked to progression of the cancer, say a group of British researchers who conducted their own study and also reviewed 58 other published studies. In the Septembe ...

Article - News Staff - Sep 3 2008 - 12:06am

New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation In Patients With Acute Coronary Syndromes Compare

MUNICH, Germany, September 3 /PRNewswire/--- ACAPULCO study showed that 10 mg Prasugrel Maintenance Dose Achieved Higher Platelet Inhibition than 150 mg Clopidogrel Maintenance Dose Among patients with acute coronary syndromes (ACS) who are administered a ...

Article - Anna Ohlden - Sep 3 2008 - 2:33am

Prasugrel Significantly Reduced New Or Recurrent Heart Attacks In Both Acute And Longer-Term Settings Following PCI, Compared Wi

MUNICH, Germany, September 3 /PRNewswire/-- A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel compared with clopidogrel significantly reduced the risk of new or recurrent heart attacks (7.4 percent vs. 9.7 percent, p ...

Article - Anna Ohlden - Sep 3 2008 - 2:33am